A New Path to Parkinson’s Treatment: Restoring Brain Health Through Gene Networks

Researchers developed a new method that looks at how genes work together in the healthy human brain and connects that information with genes or genetic changes (SNPs) linked to Parkinson’s disease. This method, called iGOLD, helps identify groups of genes (called “modules”) that may play a role in PD and can be used to find or repurpose drugs that target not just single proteins, but entire gene networks. This is especially helpful when only limited patient data is available. How iGOLD Helps with Drug Discovery Instead of looking at whether a drug hits a specific protein, iGOLD checks whether a drug can help restore a healthier pattern of gene activity. This system can also help understand how common genetic changes, often found in large population studies, affect brain function and disease development. The researchers successfully used iGOLD to identify MH (meclofenoxate hydrochloride) as a potential drug to treat Parkinson’s disease. MH Shows Promise in Protecting the Brain MH is already used in some countries for conditions like memory problems and low oxygen in the brain. In this study, MH helped improve both movement and non-motor symptoms in a mouse model of Parkinson’s disease. It worked by protecting neurons, improving energy production in cells (mitochondria), and supporting communication between brain cells (synapses). Focus on Key Brain Regions: Substantia Nigra and Hippocampus The study focused on two brain regions heavily affected by Parkinson’s: Substantia Nigra, where the loss of dopamine-producing neurons causes motor symptoms like tremors and stiffness. This region is well-known for its central role in PD. Hippocampus, which is linked to memory, mood, and other non-motor symptoms of PD such as depression and anxiety. Researchers found a specific gene module, BR7M4, to be highly active in both regions and strongly associated with Parkinson’s symptoms. Validation in Mouse Models of PD To test their findings, the researchers used a common mouse model of PD. Mice treated with MH showed: Better movement Less depressive behavior Improved brain health at the cellular level MH helped prevent brain cell death, supported healthy dopamine levels, and repaired damage in the mitochondria (the "power plants" of cells), which are often impaired in PD. MH May Help When Levodopa Fails Levodopa is the most commonly used drug for Parkinson’s, but over time, it can become less effective. MH could offer an alternative for people who no longer respond well to levodopa. The Role of σ1 Receptor This study is the first to suggest that MH may work through a protein called σ1 (sigma-1) receptor, which plays a role in protecting brain cells from stress and maintaining healthy cell communication. Why This Matters This research offers a new, systems-based approach to discovering treatments for Parkinson’s disease. It not only identifies MH as a potential new therapy but also strengthens our understanding of how different brain regions and genetic factors contribute to the disease. The hope is that with further research, MH or similar drugs could improve the quality of life for people living with Parkinson’s—especially those experiencing both motor and non-motor symptoms.